Bell Potter has a buy rating and $34.00 price target on its shares. This suggests that upside of 20% is possible from current levels. Goldman Sachs has just initiated coverage on ResMed and named it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback